Product Description
CVT-E002 (a proprietary extract) was found to be effective in the prevention of upper respiratory infections (URIs) in healthy adults, and institutionalized and community-dwelling seniors. CVT-E002 (COLD-FX¨), a patented poly-furanosyl-pyranosyl-saccharide-based extract of Panax quinquefolius is known to have immunomodulatory properties. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447298/)
Mechanisms of Action: Unknown
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Afexa Life Sciences
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Communicable Diseases|Respiratory Tract Infections
Phase 2: Healthy Volunteers|Rhinitis, Allergic, Seasonal|Communicable Diseases|Respiratory Tract Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00726401 |
CVT-E002-2007-2 | P2 |
Completed |
Rhinitis, Allergic, Seasonal |
2010-09-01 |
2019-03-18 |
Treatments |
|
NCT00435968 |
CVT-E002-2006-1 | P2 |
Completed |
Healthy Volunteers |
None |
2019-03-21 |
Treatments |
|
NCT00255307 |
CVT-E002-2005-4 | P2 |
Completed |
Communicable Diseases|Respiratory Tract Infections |
None |
2019-03-21 |
Treatments |
|
NCT00259831 |
CVT-E002-2005-3 | P3 |
Completed |
Respiratory Tract Infections|Communicable Diseases |
2006-06-01 |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|